Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Genomics Research Section, Research Technologies Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Nat Commun. 2023 Oct 18;14(1):6592. doi: 10.1038/s41467-023-42346-8.
Limited data is available on the effect of vaccination and previous virus exposure on the nature of SARS-CoV-2 transmission and immune-pressure on variants. To understand the impact of pre-existing immunity on SARS-CoV-2 airborne transmission efficiency, we perform a transmission chain experiment using naïve, intranasally or intramuscularly AZD1222 vaccinated, and previously infected hamsters. A clear gradient in transmission efficacy is observed: Transmission in hamsters vaccinated via the intramuscular route was reduced over three airborne chains (approx. 60%) compared to naïve animals, whereas transmission in previously infected hamsters and those vaccinated via the intranasal route was reduced by 80%. We also find that the Delta B.1.617.2 variant outcompeted Omicron B.1.1.529 after dual infection within and between hosts in naïve, vaccinated, and previously infected transmission chains, yet an increase in Omicron B.1.1.529 competitiveness is observed in groups with pre-existing immunity against Delta B.1.617.2. This correlates with an increase in the strength of the humoral response against Delta B.1.617.2, with the strongest response seen in previously infected animals. These data highlight the continuous need to improve vaccination strategies and address the additional evolutionary pressure pre-existing immunity may exert on SARS-CoV-2.
关于疫苗接种和先前病毒暴露对 SARS-CoV-2 传播性质和变异体免疫压力的影响,目前可用的数据有限。为了了解先前存在的免疫对 SARS-CoV-2 空气传播效率的影响,我们使用天真、鼻内或肌肉内接种 AZD1222 疫苗和先前感染的仓鼠进行了传播链实验。我们观察到传输效果的明显梯度:与天真动物相比,通过肌肉内途径接种疫苗的仓鼠的传播在三个空气传播链中减少了约 60%,而先前感染的仓鼠和通过鼻内途径接种疫苗的仓鼠的传播减少了 80%。我们还发现,在天真、接种和先前感染的传播链中,Delta B.1.617.2 变体在宿主内和宿主间双重感染后,超过了 Omicron B.1.1.529,然而,在针对 Delta B.1.617.2 具有预先存在免疫的组中,观察到 Omicron B.1.1.529 竞争力的增加。这与针对 Delta B.1.617.2 的体液反应强度增加相关,在先前感染的动物中观察到最强的反应。这些数据突出表明,需要不断改进疫苗接种策略,并解决预先存在的免疫可能对 SARS-CoV-2 施加的额外进化压力。